Icure Pharmaceutical Incorporation reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 172.76 million compared to KRW 241.7 million a year ago. Net loss was KRW 6,873.81 million compared to KRW 4,350.78 million a year ago.

Basic loss per share from continuing operations was KRW 364 compared to KRW 274.5 a year ago. Diluted loss per share from continuing operations was KRW 364 compared to KRW 228.75 a year ago. Basic loss per share was KRW 364 compared to KRW 549 a year ago.